Direct control of hepatic glucose production by interleukin-13 in mice

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 261-271

  Stanya, Kristopher J ^a   Jacobi, David ^a,b   Liu, Sihao ^a   Bhargava, Prerna ^a   Dai, Lingling ^a,c   Gangl, Matthew R ^a   Inouye, Karen ^a   Barlow, Jillian L ^d   Ji, Yewei ^e   Mizgerd, Joseph P ^f   Qi, Ling ^e   Shi, Hang ^g,h   McKenzie, Andrew N J ^d   Lee, Chih Hao ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITÉ DE TOURS   (France)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^e Department of Obstetrics Gynecology   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^h GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE SILENCING; GLUCONEOGENESIS; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIVER CELL; LIVER METABOLISM; MALE; METABOLIC DISORDER; METABOLIC REGULATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; GLUCOSE; HYPERGLYCEMIA; INSULIN RESISTANCE; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; LIVER; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; STAT3 TRANSCRIPTION FACTOR; TH1 CELLS; TH2 CELLS;

EID: 84873804024     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64941     Document Type: Article

References (57)

1. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30(2): 263-269.
2. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786): 182-197.
3. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. Betacell failure as a complication of diabetes. Rev Endocr Metab Disord. 2008;9(4): 329-343.
4. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12(3): 141-151.
5. Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 2011;14(1): 9-19.
6. Cheng Z, White MF. The AKTion in non-canonical insulin signaling. Nat Med. 2012;18(3): 351-353.
7. Inoue H, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med. 2004;10(2): 168-174.
8. Ramadoss P, Unger-Smith NE, Lam FS, Hollenberg AN. STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol Endocrinol. 2009;23(6): 827-837.
9. Lu M, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18(3): 388-395.
10. Bhargava P, Lee CH. Role and function of macrophages in the metabolic syndrome. Biochem J. 2012;442(2): 253-262.
11. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121): 860-867.
12. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3): 363-374.
13. Issad T, Kuo M. O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab. 2008;19(10): 380-389.
14. Arkan MC, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11(2): 191-198.
15. Cai D, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2): 183-190.
16. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27: 451-483.
17. Kang K, et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008;7(6): 485-495.
18. Odegaard JI, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447(7148): 1116-1120.
19. Odegaard JI, et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesityinduced insulin resistance. Cell Metab. 2008; 7(6): 496-507.
20. Ricardo-Gonzalez RR, et al. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc Natl Acad Sci U S A. 2010;107(52): 22617-22622.
21. Wu D, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332(6026): 243-247.
22. Chawla A, Nguyen KD, Goh YP. Macrophagemediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11(11): 738-749.
23. Sun S, Ji Y, Kersten S, Qi L. Mechanisms of inflammatory responses in obese adipose tissue. Annu Rev Nutr. 2012;32: 261-286.
24. Moro K, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463(7280): 540-544.
25. Neill DR, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293): 1367-1370.
26. Price AE, et al. Systemically dispersed innate IL- 13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A. 2010;107(25): 11489-11494.
27. Winer S, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8): 921-929.
28. Ji Y, et al. Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J Biol Chem. 2012;287(17): 13561-13571.
29. Saenz SA, et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature. 2010;464(7293): 1362-1366.
30. LaPorte SL, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin- 4/13 system. Cell. 2008;132(2): 259-272.
31. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12): 6166-6173.
32. Nishikawa S, Yasoshima A, Doi K, Nakayama H, Uetsuka K. Involvement of sex, strain and age factors in high fat diet-induced obesity in C57BL/6J and BALB/cA mice. Exp Anim. 2007;56(4): 263-272.
33. Nguyen KD, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480(7375): 104-108.
34. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes. 2008;57(12): 3239-3246.
35. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12): 1796-1808.
36. Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12): 1821-1830.
37. Orchansky PL, Kwan R, Lee F, Schrader JW. Characterization of the cytoplasmic domain of interleukin-13 receptor-alpha. J Biol Chem. 1999;274(30): 20818-20825.
38. Umeshita-Suyama R, et al. Characterization of IL-4 and IL-13 signals dependent on the human IL-13 receptor alpha chain 1: redundancy of requirement of tyrosine residue for STAT3 activation. Int Immunol. 2000;12(11): 1499-1509.
39. Nie Y, et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol. 2009;11(4): 492-500.
40. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab. 2000;85(10): 3770-3778.
41. Virkamaki A, Yki-Jarvinen H. Mechanisms of insulin resistance during acute endotoxemia. Endocrinology. 1994;134(5): 2072-2078.
42. Yki-Jarvinen H, Sammalkorpi K, Koivisto VA, Nikkila EA. Severity, duration, and mechanisms of insulin resistance during acute infections. J Clin Endocrinol Metab. 1989;69(2): 317-323.
43. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1): 23-35.
44. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4(3): 313-319.
45. Shimoda K, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 1996;380(6575): 630-633.
46. Takeda K, et al. Essential role of Stat6 in IL-4 signalling. Nature. 1996;380(6575): 627-630.
47. Liang HE, Reinhardt RL, Bando JK, Sullivan BM, Ho IC, Locksley RM. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol. 2011;13(1): 58-66.
48. Neill DR, McKenzie AN. Nuocytes and beyond: new insights into helminth expulsion. Trends Parasitol. 2011;27(5): 214-221.
49. Saenz SA, Noti M, Artis D. Innate immune cell populations function as initiators and effectors in Th2 cytokine responses. Trends Immunol. 2010; 31(11): 407-413.
50. Clementi AH, Gaudy AM, Zimmers TA, Koniaris LG, Mooney RA. Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse. Metabolism. 2011;60(11): 1610-1619.
51. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab. 2004;287(1):E182-E187.
52. Fritsche L, et al. IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise. Diabetologia. 2010;53(8): 1732-1742.
53. Wallenius V, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8(1): 75-79.
54. McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr Biol. 1998;8(6): 339-342.
55. Reilly SM, et al. Nuclear receptor corepressor SMRT regulates mitochondrial oxidative metabolism and mediates aging-related metabolic deterioration. Cell Metab. 2010;12(6): 643-653.
56. Liu S, et al. Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation. J Biol Chem. 2011;286(2): 1237-1247.
57. Wang X, Yang Z, Xue B, Shi H. Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology. 2011;152(3): 836-846.